PeptideCompareOrforglipron — EU research guide.
Orforglipron (Foundayo) is Eli Lilly's once-daily oral GLP-1 receptor agonist — the first non-peptide small molecule in its class, taken without fasting or water restrictions. It is FDA-approved; not yet reviewed by the EMA.
What is Orforglipron?
Unlike semaglutide or liraglutide, orforglipron is a small molecule rather than a peptide, so it survives the gut without a special absorption enhancer. It activates the GLP-1 receptor to reduce appetite and slow gastric emptying. Eli Lilly's ATTAIN Phase 3 programme supported approval in adults with obesity, or overweight with a weight-related condition.
What does the research show?
In the ATTAIN-1 trial, participants on the highest dose who completed treatment lost an average of 12.4% of body weight versus 0.9% with placebo. The FDA approved Foundayo on 1 April 2026, with a boxed warning for thyroid C-cell tumour risk shared with other GLP-1 medicines.
EU legal status
Not approved in the EU as of mid-2026. Orforglipron is a patented pharmaceutical, not a generic research peptide — and since it isn't even a peptide, it falls outside the scope of most RUO peptide suppliers entirely. Material marketed as “oral orforglipron” by unregulated sellers cannot be verified.
Molecular information
Pharmacokinetics
Potency retained over time
Each line is one storage condition: it starts at 100% and falls as potency is lost. Above the dashed 80% line the material is considered reliable — hover for exact values.
⚠ A structural estimate, derived from each compound's sequence length, cyclisation and oxidation-, deamidation- and light-sensitive residues. Indicative only — not lab-measured per batch.
GLP-1 compounds across EU suppliers
COA-verified EU vendors · Updated monthly
References
- The peer-reviewed report of the pivotal ATTAIN-1 trial: 3,127 adults, 72 weeks, placebo-controlled. It shows dose-dependent weight loss and gastrointestinal adverse events as the main reason for stopping; it is manufacturer-funded and does not cover long-term outcomes. Wharton S, Aronne LJ, Stefanski A, Alfaris NF, Ciudin A, Yokote K, Halpern B, Shukla AP, Zhou C, Macpherson L, Allen SE, Ahmad NN, Klise SR; ATTAIN-1 Trial Investigators. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025;393(18):1796-1806. DOIPubMed 40960239
- The official US label: indication, boxed warning for thyroid C-cell tumour risk, elimination half-life, storage (room temperature, protect from light) and the pooled pivotal-trial results. This is the licensed tablet, not vendor 'research' material. Eli Lilly and Company. FOUNDAYO (orforglipron) tablets: US prescribing information. US Food and Drug Administration; revised 04/2026. Source
- The UK regulator's announcement that orforglipron was authorised in August 2026 for weight management and for glycaemic control in type 2 diabetes. It concerns the UK only and is not an EU decision. Medicines and Healthcare products Regulatory Agency. UK first in Europe to authorise orforglipron for weight management and type 2 diabetes. GOV.UK; 10 August 2026. Source
- Manufacturer press release on the ATTAIN-2 topline (adults with obesity and type 2 diabetes). A company statement, not a peer-reviewed paper; it is included for context on the second pivotal trial. Eli Lilly and Company. Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity. Company press release (ATTAIN-2 topline). Source